Rowlandmiller & PARTNERS.ADV Has $11.53 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Rowlandmiller & PARTNERS.ADV lessened its stake in Johnson & Johnson (NYSE:JNJ) by 1.0% in the first quarter, HoldingsChannel reports. The firm owned 69,525 shares of the company’s stock after selling 669 shares during the period. Johnson & Johnson makes up approximately 2.4% of Rowlandmiller & PARTNERS.ADV’s holdings, making the stock its 10th largest holding. Rowlandmiller & PARTNERS.ADV’s holdings in Johnson & Johnson were worth $11,530,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of JNJ. Lantz Financial LLC grew its position in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock valued at $1,986,000 after buying an additional 377 shares during the period. Sulzberger Capital Advisors Inc. purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth $453,000. Horan Securities Inc. raised its holdings in Johnson & Johnson by 1.3% in the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after purchasing an additional 90 shares during the period. Strategic Financial Concepts LLC raised its holdings in Johnson & Johnson by 57.9% in the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after purchasing an additional 1,271 shares during the period. Finally, State of Wyoming raised its holdings in Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock worth $1,487,000 after purchasing an additional 10,279 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.8%

JNJ stock opened at $156.45 on Wednesday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock has a market capitalization of $376.43 billion, a price-to-earnings ratio of 23.53, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The firm’s fifty day simple moving average is $153.52 and its two-hundred day simple moving average is $153.69.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.32%. The ex-dividend date was Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio is 57.84%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent analyst reports. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Raymond James decreased their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research report on Monday, April 14th. Bank of America decreased their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, April 10th. Leerink Partnrs cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.